A new generic formulation of pyridostigmine bromide — a muscle-strengthening medication sold under the brand name Mestinon — is now available for people with myasthenia gravis (MG) in the U.S. [read more in Myasthenia Gravis News] The post New generic version of Mestinon as oral syrup available in U.S. appeared first on Conquer Myasthenia Gravis ..read more

Scientific Reports shares results from a study that looks at disease burden. Public domain digital conversations about MG were analyzed to describe mindsets and sentiments about the disease, its burden, and its treatments among men and women with MG and, more specifically, those treated with steroids and those receiving IVIg. The post Read study results on patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations appeared first on Conquer Myasthenia Gravis ..read more

The post Ask An Expert – What you should know about the newest therapy options. appeared first on Conquer Myasthenia Gravis ..read more

Conquer MG is seeking nominations for qualified individuals to serve on its Board of Trustees. This is an incredible group of people who care deeply about the well-being of those who experience or know someone with myasthenia gravis. Our role as board members is to help people with myasthenia gravis and their caregivers access information, resources, and community as a way of empowering them to take charge of their disease and how it uniquely impacts their lives. Click here to apply! Email your completed application to Michelle Weber, info@myastheniagravis.org. The post Conquer MG is seeking ..read more

  Where: Chicago Marriott Oak Brook, 1401 W. 22nd Street, Oak Brook, IL  Join us for a day full of information and support from experts who know.  Takeaways from this event include:  Time with MG patients and medical experts to get your questions answered.  Information and educational materials.  Connect with local businesses that cater to MG patients and specialize in their needs.  Learn more about MG research and treatment developments from MG experts and corporate industry leaders.  This event is FREE to attend. You’ll find chairs and resting are ..read more

UCB Announces U.S. FDA Approval of RYSTIGGO[®] (rozanolixizumab-noli) for the Treatment of Adults with Generalized Myasthenia Gravis What you need to know: This is a new therapy that is designed as a monoclonal antibody that binds to the neonatal Fc receptor (FcRN). The delivery of this therapy is subcutaneous injection – so it’s quicker and more convenient than infusion therapies that take hours. Rystiggo is approved to treat the most common type of MG (AChR-antibody) and also approved to treat MuSK-antibody (muscle-specific kinase) myasthenia – which is typically more severe and hasn’t resp ..read more

COVID continues to be a concern if you are immunocompromised or have a weakened immune system because of a medical condition or a treatment for a condition. This is the case if you have myasthenia gravis, and are taking immuno-suppressant medication. The Centers for Disease Control continues to recommenf that those who are immunocompromised or have a weakened immune system because of a medical condition or a treatment for a condition keep their vaccinations up to date. In late 2022, Linda Loland and Victor Yipp both experienced worsening MG breathing and swallowing symptoms when they contracte ..read more

Speaker: Pritikanta Paul, MD, Department of Neurology, UI Health/ University of Illinois at Chicago Register Now! Emerging Therapies for MG Tuesday, October 25, 2022; 6:30pm Central Speaker: Pritikanta Paul, MD, University of Illinois at Chicago After years of research and clinical trials, a number of new therapies for myasthenia gravis have arrived or will do so soon. Instead of suppressing a person’s entire immune system (as with drugs like prednisone, azathioprine, and others), these therapies target and interrupt the immune system missteps caused by MG. For many, this means quicker res ..read more

Useful information…at your fingertips. Topic Title Contributor Published Financial assistance for MG patients – Sept 30 2022 Staff 2022 Sept MG Activities of Daily Living (MG-ADL) Scale Kourosh Rezania, MD 2022 Sept Patient Experience with Pyridostigmine Staff 2022 Sept Update – Myasthenia Gravis and Coronavirus Conquer MG Medical Advisory Board 2020 Dec Myasthenia Gravis and Telemedicine Rabia Malik, MD 2022 Oct MG Clinical Trials: Your Questions Answered Rabia Malik, MD 2020 Jan IVIg, Plasma Exchange, and Emerging MG Treatments Ryan Jacobson, MD 2019 July Men’s &a ..read more

Are medical costs overwhelming you? These programs may provide relief. Click the links to learn about who’s eligible and what each program covers. Status (open/ waitlisting/ closed) is current as of September 30, 2022: The Assistance Fund is accepting new enrollments for individuals who have myasthenia gravis. This program helps with out-of-pocket medical costs. The National Organization for Rare Diseases (NORD)‘s financial assistance program is temporarily waitlisting MG patients. (In other words, get on the waitlist.) NORD helps with the cost of insurance premiums, office visits, medicati ..read more